Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drug pipeline
Source: SeekingAlpha
2026-02-25 10:34:55 ET
More on Viatris
- Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
- 44th Annual J.P. Morgan Healthcare Conference
- Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Viatris, Opus gain as FDA to review label expansion for eyecare drug
- Viatris gains as UBS upgrades to Buy on outlook and pipeline
Read the full article on Seeking Alpha
For further details see:
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drug pipeline
Viatris Inc.
NASDAQ: VTRS
VTRS Trading
3.0% G/L:
$14.405 Last:
2,636,674 Volume:
$14.17 Open:
VTRS Latest News
February 27, 2026 03:57:23 pm
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
February 26, 2026 06:55:00 am
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
VTRS Stock Data
$18,451,353,349
1,140,252,173
N/A
503
N/A
Pharmaceuticals
Healthcare
US
Canonsburg
